Sanofi Supports the International Diabetes Federation and the Chinese Diabetes Society to Launch Study on Type 1 Diabetes in China
Sanofi today announced a partnership with the International Diabetes Federation (IDF) and the Chinese Diabetes Society (CDS) to support the launch of an innovative study named ‘3C Study on Type 1 Diabetes in China – Coverage, Cost and Care’. The study aims to gather data and information on the coverage, cost and care for people with Type 1 diabetes in China. The results will be used to advocate for Type 1 diabetes improved care. The ‘3C Study on Type 1 Diabetes in China’ will be carried out in Beijing and Shantou, Guangdong Province, at primary, secondary, and tertiary healthcare institutions, and the results are expected to be announced at the World Diabetes Congress in December 2011 in Dubai.
Type 1 diabetes is a form of diabetes mellitus that results from autoimmune destruction of insulin-producing beta cells of the pancreas. The disease is fatal unless treated with multiple injection of insulin daily such as Basal Bolus or continuous infusion of insulin for the life time. The disease is often diagnosed in individuals of young age, and people with Type 1 diabetes risk suffering from complications such as blindness, kidney failure, heart disease, or amputation if the disease is not well controlled.
Riccardo Perfetti, Vice President, Medical Affairs from Sanofi mentioned: “Based on our long standing expertise as a leader in diabetes care, we realized that therapeutic innovations alone are not enough to achieve the optimal patient outcome. Our goal is to provide comprehensive care that best serves the needs of patients on their journey of managing diabetes; this project represents an important step toward this commitment where we contribute to understand the needs of people with Type 1 diabetes in China and help them manage their disease.”
Professor Jean-Claude Mbanya, President of IDF personally presided over the launch ceremony of the study held in Beijing, China. He pointed out that: “The ‘3C Study on Type 1 Diabetes in China’ marks a new milestone in the fight against Type 1 diabetes in China and worldwide. Specifically, it aims to describe critical components of Type 1 diabetes such as coverage, disease burden, health economics, and status of care. This study also exemplifies the shared commitment of the international and Chinese scientific communities and leading providers of diabetes care such as Sanofi.”
Professor Ji Linong, President of CDS, added that: “The ‘3C Study on Type 1 Diabetes in China’ will build a foundation for a Type 1 diabetes registry with the ultimate objective of transforming clinical practice and policy environment to improve the standard of care. According to the available data, there are at least 1 million people with Type 1 diabetes in China. The study is expected to shed some new light on the impact of Type 1 diabetes and the situation of patient care.”
Fabrice Baschiera, General Manager, Pharmaceutical Operations, Sanofi China, said: “Changes have to start with a deep understanding of the situation. It is our responsibility to work in this field and it is an honor to support the ‘3C Study on Type 1 Diabetes in China’”. In addition to China, Sanofi also supports Type 1 research and education with many academic and patients associations all over the world.